The Kimberling Usher Research Laboratory in the Institute for Vision Research is pleased to announce an increase in our campaign goal to $10 million.
July 13th, 2018
December 27th, 2017
The pharmaceutical company Spark Therapeutics recently announced FDA approval1,2 of a gene therapy known as Luxturna, which has been shown to improve vision in patients with an extremely rare inherited eye disease caused by mutations in the gene RPE65.
November 30th, 2017
Scientists at the WIVR recently published a report in which they tested the efficiency and retinal cell type targeted by 7 different serotypes of adeno-associated virus (AAV) in the human retina.